Loading
Adding durvalumab to first-line chemotherapy delayed progression in advanced endometrial cancer, and adding the PARP inhibitor olaparib to durvalumab maintenance helped further in mismatch repair-proficient tumours.
Phase 3 trial of 718 patients with newly diagnosed advanced or recurrent endometrial cancer randomised to carboplatin-paclitaxel alone, with durvalumab followed by durvalumab maintenance, or with durvalumab followed by durvalumab plus olaparib maintenance.
Progression-free survival hazard ratios were 0.71 for durvalumab and 0.55 for durvalumab plus olaparib versus control; in mismatch repair-deficient disease both immunotherapy arms performed similarly (hazard ratio about 0.42), whereas olaparib added benefit in proficient disease (0.57 versus 0.77).
Durvalumab-based chemo-immunotherapy is a third first-line option with RUBY and NRG-GY018, and durvalumab plus olaparib maintenance is approved for mismatch repair-proficient disease in some regions.
Shares DUO-E / GOG-3041 / ENGOT-EN10, Advanced or recurrent endometrial cancer, Durvalumab, Carboplatin.
Shares Advanced or recurrent endometrial cancer, Durvalumab.
Shares Olaparib, Durvalumab.
Shares Olaparib, Carboplatin.
Shares Olaparib, Durvalumab, Carboplatin.
Shares Durvalumab, Carboplatin.
Shares Olaparib, Durvalumab.
Shares Olaparib, Durvalumab, Carboplatin.